Salubris Biotherapeutics
CompanyUnited States
Salubris Biotherapeutics develops 2 assets, the furthest in phase 2 (JK06 in breast cancer). Mostly other and protein or enzyme; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- 6
- Trials
- 0
- Signals
Pipeline
2Targets 5T4-expressing tumor cells to deliver a cytotoxic drug payload.
Phase 2, Other, breast cancer, locally advanced or metastatic solid tumors
Neuregulin fusion protein selectively activates ERBB4 while blocking ERBB3, promoting cardiac repair and function.
Phase 2, Protein or enzyme, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials6
- Similar companies6